Effects of Nicotinamide Riboside (Vitamin B3) in Patients With Ataxia Telangiectasia.
This clinical trial investigates the effects of nicotinamide riboside (vitamin B3) on the disease course of patients with ataxia telangiectasia.
Patients will be treated during four consecutive months with nicotinamide riboside (25mg/kg/day), followed by a washout period of two months.
Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters.
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy